Find information on thousands of medical conditions and prescription drugs.

Bosentan

Bosentan is an endothelin receptor antagonist important in the treatment of pulmonary artery hypertension.

Home
Diseases
Medicines
A
B
Baciim
Bacitracin
Baclofen
Bactrim
Bactroban
Barbexaclone
Barbital
Baros
Basiliximab
Baycol
Beclamide
Beclometasone
Beclovent
Beconase
Beldin
Benadryl
Benazepril
Bendroflumethiazide
Benserazide
Bentiromide
Benylin
Benzaclin
Benzalkonium chloride
Benzocaine
Benzonatate
Betacarotene
Betadine
Betahistine
Betamethasone
Betaxolol
Bextra
Biaxin
Bibrocathol
Bicalutamide
Bicillin
Biclotymol
Biotin
Bisoprolol
Bleomycin
Blocadren
Boldenone
Boniva
Bontril
Bosentan
Bravelle
Brethaire
Brevibloc
Brevicon
Bricanyl
Bromazepam
Bromelain
Bromhexine
Bromocriptine
Brompheniramine
Bronkodyl
Bronopol
BSS
Bucet
Budesonide
Bumetanide
Bupivacaine
Buprenex
Buprenorphine
Buserelin
Buspar
Buspirone
Busulfan
Butalbital
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


The addition of sildenafil to bosentan therapy in the treatment of pulmonary arterial hypertension
From CHEST, 10/1/05 by Stephen C. Mathai

PURPOSE: Pulmonary arterial hypertension (PAH) is a progressive disease that often results in right heart failure and death. Combination therapy targeting several pathways involved in the pathogenesis of pulmonary hypertension has been recommended. In this study, we review our experience with the addition of sildenafil to bosentan therapy in patients with PAH.

METHODS: Eighteen patients with pulmonary hypertension (12 with PAH related to connective tissue disease, 4 with IPAH, 2 with PAH related to anorexigen use) who received combination therapy with bosentan and sildenafil between January 2002 and April 2005 were included. Bosentan was used as first-line therapy. Sildenafil was added for clinical deterioration based upon symptoms, New York Heart Association (NYHA) assessment, and/or deterioration in six minute walk distance (6MWD). Demographics, clinical data, and hemodynamic data were collected at baseline; clinical data were again collected just prior to adding sildenafil and 1-3 months after starting sildenafil.

RESULTS: Of 18 patients in whom sildenafil was added to bosentan therapy, 4 (22.2%) discontinued therapy due to side effects. One patient died from complications related to progressive right heart failure. Five patients required additional therapy due to disease progression. Prior to starting bosentan therapy, the mean 6MWD was 281.5 [+ or -] 115.2m. The mean 6MWD after initiation of sildenafil improved significantly compared to 6MWD prior to initiation (223.6 [+ or -] 106.5m vs. 307.6 [+ or -] 122.5m, p=0.04). The proportion of patients who were considered NYHA class I or II after the addition of sildenafil therapy versus prior to initiation also increased significantly (0% vs. 27.7%, p = 0.02).

CONCLUSION: Overall, the addition of sildenafil to bosentan therapy improved NYHA class and functional capacity assessed by 6MWD in this group of patients with pulmonary arterial hypertension. However a significant proportion of patients had to discontinue sildenafil due to adverse effects or required escalation in therapy due to clinical deterioration.

CLINICAL IMPLICATIONS: Addition of sildenafil to bosentan therapy may be of benefit in patients with pulmonary arterial hypertension. Long-term follow-up is needed to ascertain the clinical efficacy and tolerability of this combination of therapies.

DISCLOSURE: Stephen Mathai, None.

Stephen C. Mathai MD * Micah R. Fisher MD Traci Housten-Harris RN Reda E. Girgis MB, BCh Paul M. Hassoun MD Johns Hopkins University, Baltimore, MD

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Bosentan
Home Contact Resources Exchange Links ebay